(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.
The Cambridge, England-based pharmaceutical company announced that phase three trials of its sipavibart long-acting antibody demonstrated a statistically significant reduction in incidences of symptomatic Covid-19 among patients with compromised immune systems.
Iskra Reic, executive vice president for Vaccines & Immune Therapies, commented: "Immunocompromised patients currently have limited or no options for Covid-19 protection and continue to face a significant burden of disease, despite often being fully vaccinated.
"Sipavibart has the potential to prevent Covid-19 in the immunocompromised and we will now work with regulatory authorities globally to bring sipavibart to these vulnerable patients."
AstraZeneca shares were down 0.4% to 12,126.00 pence each in London on Thursday morning.
By Elijah Dale, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Astrazeneca (AZN)
